Previous Article | Next Article ![]()
Journal of Clinical Microbiology, May 2008, p. 1606-1613, Vol. 46, No. 5
0095-1137/08/$08.00+0 doi:10.1128/JCM.02328-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

perov,1
Magdalena Grce,1* and
Ruth Tachezy2
Division of Molecular Medicine, Rudjer Bo
kovi
Institute, Bijenicka 54, Zagreb 10002, Croatia,1
Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic,2
Research Program Infection and Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany3
Received 4 December 2007/ Returned for modification 14 January 2008/ Accepted 23 February 2008
Human papillomaviruses (HPVs) have been recognized as etiologic factors in a variety of diseases. Due to the large number of HPV types, methods for HPV genotyping are difficult to standardize. Despite this fact, several methods exist, and some of them are available commercially. In this study, we evaluated the Roche Diagnostics linear array (LA) HPV genotyping assay, the Innogenetics INNO-LiPA (line probe assay [LiPA]), and two noncommercial reverse line blot (RLB) assays based on either primers GP5+ and GP6+ (GP) or newly designed broad-spectrum primers BSGP5+ and BSGP6+ (BS). The reliabilities of these assays were tested with a wide spectrum of HPV types less prevalent in cervical samples. This is the first study to compare the performance of the most widely used HPV genotyping methods with selected samples positive for low-prevalence HPV types. We focused on interassay agreement, both overall and type specific, in cases with single and/or multiple HPV infections. Interassay agreement was moderate in cases of single HPV infections and poor in cases of multiple HPV infections. The LA and the BS-based RLB assays found a higher rate of cases positive for multiple HPV types than LiPA and the GP-based RLB assay. The weakest capability in detecting multiple HPV infections was observed for LiPA. The use of only one assay in epidemiological and clinical studies might lead to biased conclusions. Therefore, a universally evaluated and agreed upon HPV typing assay or a combination of current assays is needed for possible clinical applications, and knowledge of their limitations is advised.
kovi
Institute, Bijenicka cesta 54, P.O. Box 180, Zagreb HR-10002, Croatia. Phone: 385 1 4561110. Fax: 385 1 4561110. E-mail: grce{at}irb.hr
Published ahead of print on 5 March 2008.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»